En vivo
Clinical OMICsInfant Brain Development Sheds Light on Parkinson’s Link with AutismClinical OMICsAlzheimer’s Genetic Risk Loci: 16 New CandidatesEndpoints NewsActing FDA commissioner pledges to prevent political interference in rare disease meetingEndpoints NewsDimension seeks up to $750M for third life sciences fund after string of successEndpoints NewsElevance talks 'practical' AIEndpoints NewsMammalian hair, roof leaks: Novo's Catalent site in Indiana under FDA scrutiny once againFierceBiotechAutobahn races toward pivotal trial after thyroid hormone mimic eases bipolar depression in ph. 2Lonza NewsLonza, Stipple Bio Sign ADC Licensing Deal - Contract PharmaEndpoints NewsHikma to funnel $267M to Ohio; Cingulate gets CRL for ADHD drugCellPaleogenomes reveal the evolutionary relationship between modern and cave lionsEndpoints NewsLilly, Boehringer retrench in Germany on proposed health spending cutsEndpoints NewsSupreme Court sides with Hikma in 'skinny label' case
Endpoints News 27 feb 2026

Novo Nordisk’s ‘strategic conundrum’: How being anchored to the past could cost it the future

Novo Nordisk’s ‘strategic conundrum’: How being anchored to the past could cost it the future

Original
Contenido no disponible. Consulta la fuente original.